Alamar Biosciences, Inc.
About Alamar Biosciences, Inc.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $26.0M
- Net income
- -$21.3M
- Total assets
- $186.5M
- Market cap
- $1.4B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- Shares outstanding
- 66.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 17, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $21.3M in FY2026.
- Trading 19% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alamar Biosciences, Inc..
Write a review
News about Alamar Biosciences, Inc.
News & sentiment via Polygon.io
